ND Committee Review
Internal Medical Policy Committee 1-22-2020 Adopt new pre-certification policy
Internal Medical Policy Committee 11-19-2020 Description updated, minor wording changes, no clinical content change
Internal Medical Policy Committee 11-23-2021 Annual review, no clinical content change
Internal Medical Policy Committee 5-24-2022 Removed NCCN recommendations and added this statement "Siltuximab (Sylvant) may be considered medically necessary for treatment of any of the current category 1 or 2A NCCN recommendations.", updated the experimental/investigational statement, updated dx codes